Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor cell proliferation related kinase -c-Kit kinase. In the phase # study, patients who
failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance
were treated with anlotinib or placebo, the anlotinib group PFS and OS were 5.37 months and
9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months. Therefore, the
combination of Anlotinib and Penpulimab (a new PD-1 inhibitor) is attempted for the treatment
of advanced non-small-cell lung cancer (NSCLC) participants who have progressed following
prior PD-1 or PD-L1 Inhibitors treatment, to further improve the patient's PFS or OS.
Phase:
Phase 2
Details
Lead Sponsor:
Hunan Cancer Hospital
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Henan Cancer Hospital